|drug684||Cambridge Validated Viral Detection Method Wiki||1.00|
|drug2781||Radiological Detection Wiki||1.00|
|drug2689||Public Health England Gold Standard Wiki||1.00|
|D000208||Acute Disease NIH||0.71|
|D014777||Virus Diseases NIH||0.10|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
In COVID-19 pandemic, it is of critical importance to identify a rapid and simple diagnostic method to be used in clinical settings to timely inform and refine strategies that can prevent, control, and stop the spread of SARS-CoV-2. The 2019-nCoV IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is a qualitative, membrane-based immunoassay for the detection of immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies to SARS-CoV-2 in whole blood, serum or plasma specimen. Clinical specimens from patients who were suspected of being infected with 2019-nCoV will be used to evaluate the performance of the assay.
Description: Patients positive are serially tested with SARSCoV-2 lgM / IgG Rapid Test to evaluate the immune response in IgG negative patients and the reliability of the test in those patients who develop clinical signs of SARS-CoV-2 during the trial.Measure: Evaluation of the rate of SARS-CoV-2 positive cancer patients and health professionals in a comprehensive cancer center or in a cancer setting. Time: 6 months
Description: The 2019-nCoV IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) was compared with a leading commercial Polymerase Chain ReactionMeasure: Evaluation of test accuracy Time: 3 months
Description: Multiplex immunoassayMeasure: Interleukin-6 quantification Time: 3 months
Description: Multiplex immunoassayMeasure: Interleukin-2 quantification Time: 3 months
Description: Multiplex immunoassayMeasure: Interleukin-1 quantification Time: 6 months
Description: Multiplex immunoassayMeasure: Tumor Necrosis Factor (TNF) quantification Time: 3 months
Description: Multiplex immunoassayMeasure: Interferon gamma quantification Time: 3 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports